BioNTech And The Coalition For Epidemic Preparedness Innovations Announced A Strategic Partnership To Advance mRNA-based Vaccine Candidates With The Development Of BNT166 For The Prevention Of Mpox (Formerly Monkeypox). CEPI Commits Funding Of Up To $90M
Portfolio Pulse from Benzinga Newsdesk
BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a strategic partnership to advance mRNA-based vaccine candidates, including the development of BNT166 for the prevention of Mpox. CEPI has committed funding of up to $90 million for this project.
September 18, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's partnership with CEPI and the development of BNT166 could potentially boost the company's stock in the short term due to the significant funding commitment from CEPI.
The news of a strategic partnership with CEPI and the development of a new vaccine candidate, BNT166, is directly related to BioNTech's core business. The commitment of up to $90 million in funding from CEPI is a significant financial boost, which could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100